[Skip to Navigation]
January 1990

Cerebeller Ataxia

Author Affiliations

Hôpital Cardio-Vasculaire Service de Neurologie 59 Boulevard Pinel 69003 Lyon, France

Arch Neurol. 1990;47(1):12. doi:10.1001/archneur.1990.00530010018008

To the Editor.  —We do not think that Klein et al1 in their 1986 publication gave dosages identical to those used in our original publications in 1980 and 1981.2,3 We never used 16 mg/kg of the levorotatory form of 5-hydroxytryptophan with 6 mg/kg of benserazide; 16 mg/kg of 5 hydroxytryptophan (racemic) with 6 mg/kg of benserazide were actually given. The levorotatory form of 5-hydroxytryptophan being the active form of the molecule, they actually gave a double dose of 5-hydroxytryptophan (levarotatory), when compared with our protocol. But, with the important doses of benserazide that they gave (6 mg/kg), the final disposable dose of the levorotatory form of 5-hydroxytryptophan for the central nervous system might have been multiplied by three or four when compared with our protocol. Moreover, they used a pretreatment with benserazide, which we did not mention, that might have provoked an exploding serotoninergic effect with no levorotatory

Add or change institution